Floatz logo

Sofosbuvir

HIV CDC Category A1

University of California, San FranciscoSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

62 Active assets in the HIV CDC Category A1 cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
Efavirenz
The Cleveland Clinic
Phase 4BBB
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Dolutegravir
Instituto Mexicano del Seguro Social
Phase 4BBB
Abacavir
Germans Trias i Pujol Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Sofosbuvir is also rated in:

hepatitis C virus infectionDormant
A
Indicative ·
82 / 100
View asset →
chronic hepatitis C virus infectionDormant
A
Indicative ·
81 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →